CHMA News and Press, Chiasma Inc. From 06/26/20

MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide Conference call and webcast scheduled today at 2 pm ET NEEDHAM, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. ...

If Chiasma Inc.'s (CHMA) Mycapssa is approved as an orphan drug by the FDA on or around June 26, 2020, as anticipated, as the first and only FDA approved oral therapy (or pill) to treat acromegaly, a rare condition affecting 8,000 patients in the US, our analysis concludes Chiasma Inc.'s share...

Chiasma, Inc. (CHMA) Q1 2020 Earnings Conference Call May 7, 2020 17:00 ET Company Participants Dawn Schottlandt - Vice President, IR & Corporate Communication Raj Kannan - Chief Executive Officer Anand Varadan - Executive Vice President & Chief Commercial Officer Bill ...

Image source: The Motley Fool. Chiasma Inc   (NASDAQ: CHMA) Q1 2020 Earnings Call May 7, 2020 , 5:00 p.m. ET Operator Continue reading

Chiasma (NASDAQ: CHMA ): Q1 GAAP EPS of -$0.36 misses by $0.04 . Cash, cash equivalents and marketable securities of $79.3M Press Release More news on: Chiasma, Inc., Earnings news and commentary, Healthcare stocks news, ,

NEEDHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases, today reported...

NEEDHAM, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it will host a conference call and live audio webcas...

NEEDHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases, today announ...

NEEDHAM, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced its entry into a revenue interest financing agreement wit...

Image source: The Motley Fool. Chiasma Inc   (NASDAQ: CHMA) Q4 2019 Earnings Call Mar 16, 2020 , 5:00 p.m. ET Operator Continue reading